The Value of mNGS in Diagnosis of Pulmonary Infection

Launched by YUNFENG HOU · Mar 6, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "The Value of mNGS in Diagnosis of Pulmonary Infection," is studying a new method called metagenomic next-generation sequencing (mNGS) to see how well it can help diagnose pulmonary infections. Researchers are looking at data from 50 patients who were admitted to the hospital with suspected lung infections. These patients had samples taken from their lungs and sputum (mucus from the respiratory tract) to compare the results of mNGS with traditional methods of detecting pathogens, or germs, that cause infections.

To be eligible for this study, patients must have been diagnosed with a pulmonary infection between January 1, 2020, and October 31, 2023. This includes people showing symptoms like a recent cough, fever, or difficulty breathing, along with specific findings on chest CT scans. However, patients who did not undergo a procedure called bronchoscopy or who lack essential clinical data will not be included. Participants can expect their samples to be analyzed to help determine whether the new testing method is more effective in identifying the germs responsible for their infections compared to standard testing methods. This trial aims to improve how doctors diagnose lung infections, which could lead to better treatment options for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria: Patients meeting diagnostic criteria for pulmonary infection between January 1, 2020 and October 31, 2023. Patients with pulmonary infection were diagnosed with new or worsening focal or diffuse infiltrating lesions on chest CT accompanied by at least one of the following four pneumonic-related clinical manifestations: (1) Recent cough, sputum, or aggravation of existing respiratory symptoms with or without purulent sputum, chest pain, dyspnea, and hemoptysis; ② Heat, T≥38℃; ③ Signs of lung consolidation and/or smell and moist rales; ④ Peripheral blood white blood cell count \> 10\*109/L or \< 4\*109/L.
• • Exclusion criteria: ① The patient did not undergo bronchoscopy; Absence of clinical or laboratory data.